High-dose liposomalamphotericinB was effective and safe in the treatment of neonatal candidiasis.
2
LiposomalamphotericinB is very effective and safe but currently unaffordable because of its high price.
3
This association of renal and hepatotoxicity with liposomalamphotericinB has not previously been reported in children.
4
LiposomalamphotericinB was always more active than the other drugs against all the microorganisms except C. bertholletiae.
5
Fungal eradication was more rapid in patients treated early with high doses and in patients who received high-dose liposomalamphotericinB as first-line therapy.
6
The next best alternative was a combination of liposomalamphotericinB with paromomycin with an incremental cost-effectiveness of $652 per death averted.